RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/26373277http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/26373277http://www.w3.org/2000/01/rdf-schema#comment"Immune checkpoint blockade of the programmed cell death protein 1 (PD-1) pathway by monoclonal antibodies (Abs) has shown promising clinical benefit in the treatment of multiple cancer types. We elucidated the contribution of the fragment crystallizable (Fc) domains of anti-PD-1 and anti-PD-ligand 1 (L1) Abs for their optimal anti-tumor activity. We revealed that distinct Fcγ receptor (FcγRs) dependency and mechanisms account for the in vivo activity of anti-PD-1 versus anti-PD-L1 Abs. Anti-PD-1 Abs were found to be FcγR independent in vivo; the presence of FcγR-binding capacity compromises their anti-tumor activity. In contrast, the anti-PD-L1 Abs show augmented anti-tumor activity when activating FcγR binding is introduced into the molecules, altering myeloid subsets within the tumor microenvironment."xsd:string
http://purl.uniprot.org/citations/26373277http://purl.org/dc/terms/identifier"doi:10.1016/j.ccell.2015.08.004"xsd:string
http://purl.uniprot.org/citations/26373277http://purl.uniprot.org/core/author"Ravetch J.V."xsd:string
http://purl.uniprot.org/citations/26373277http://purl.uniprot.org/core/author"Korman A.J."xsd:string
http://purl.uniprot.org/citations/26373277http://purl.uniprot.org/core/author"Selby M."xsd:string
http://purl.uniprot.org/citations/26373277http://purl.uniprot.org/core/author"Dahan R."xsd:string
http://purl.uniprot.org/citations/26373277http://purl.uniprot.org/core/author"Engelhardt J."xsd:string
http://purl.uniprot.org/citations/26373277http://purl.uniprot.org/core/author"Sega E."xsd:string
http://purl.uniprot.org/citations/26373277http://purl.uniprot.org/core/date"2015"xsd:gYear
http://purl.uniprot.org/citations/26373277http://purl.uniprot.org/core/name"Cancer Cell"xsd:string
http://purl.uniprot.org/citations/26373277http://purl.uniprot.org/core/pages"285-295"xsd:string
http://purl.uniprot.org/citations/26373277http://purl.uniprot.org/core/title"FcgammaRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis."xsd:string
http://purl.uniprot.org/citations/26373277http://purl.uniprot.org/core/volume"28"xsd:string
http://purl.uniprot.org/citations/26373277http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/26373277
http://purl.uniprot.org/citations/26373277http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/26373277
http://purl.uniprot.org/uniprot/#_A0A0B4J1E6-mappedCitation-26373277http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/26373277
http://purl.uniprot.org/uniprot/#_A0A0B4J1G1-mappedCitation-26373277http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/26373277
http://purl.uniprot.org/uniprot/#_A0A0B4J1M6-mappedCitation-26373277http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/26373277
http://purl.uniprot.org/uniprot/#_E9PUV2-mappedCitation-26373277http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/26373277
http://purl.uniprot.org/uniprot/#_E9PVR4-mappedCitation-26373277http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/26373277
http://purl.uniprot.org/uniprot/#_E9Q415-mappedCitation-26373277http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/26373277
http://purl.uniprot.org/uniprot/#_Q7TMW9-mappedCitation-26373277http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/26373277
http://purl.uniprot.org/uniprot/#_Q02242-mappedCitation-26373277http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/26373277
http://purl.uniprot.org/uniprot/#_P08101-mappedCitation-26373277http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/26373277